Developer docs
API playgroundTry for free, no card

Search company profiles

Medosome Biotec

Full company profile

uuid000cjmm

Namestring
Medosome Biotec
Legal namestring
Medosome Biotec, LLC
Websiteurl
mdbiotec.com
Company typeenum
Private
Founded yearstring
-
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersAlachua, United States
HQ citystring
Alachua
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pediatric biotechnology, rare disease therapeutics, precision medicine diagnostics, probiotic drug delivery, companion diagnostics
Industry5 codes
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Laboratories621511
  • Pharmaceutical and Medicine Manufacturing3254
SIC code4 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Pediatric Biopharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Drug Development and Commercialization
TypeLicensing Royalties
Description

Developing early-stage technologies from preclinical through IND/Phase I, with strategic partnerships for FDA marketing approval and commercialization of pharmaceutical products.

mdbiotec.com
2Genetic Testing Services
TypeSubscription Recurring
Description

CLIA certified genetic testing laboratory providing companion diagnostics including GSTZ1 haplotyping and HIV/HCV subpopulation testing for personalized dosing.

mdbiotec.com
3SBIR/STTR Grant Funding
TypeProfessional Services
Description

Pursuing Small Business Innovation Research and Small Business Technology Transfer grants from government agencies including HHS/NIH, NSF, DOD, DOE, USDA.

mdbiotec.com
4Spin-off Companies
TypeLicensing Royalties
Description

Formation of subsidiary companies like Nuteric Natural Health Products for commercializing product lines, with faculty collaborators benefiting from spin-off entities.

mdbiotec.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Pricing details1 tier
1Precision medicine and genetic testing services
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing available; services provided through clinical and healthcare institutional channels

mdbiotec.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Nuteric
Description

Anti-diarrheal beverage for pediatric diarrhea with pro-absorptive and anti-secretory properties, currently in clinical trial in Bangladesh

mdbiotec.com
+4 more records
Core offering1 text field

Medosome Biotec develops and commercializes early-stage biotechnologies for pediatric rare and tropical diseases, including small molecule drugs (DCA, MyeGen-0298), a Lactobacillus-based oral peptide delivery platform, biological therapeutics (Ang-(1-7)), and CLIA-certified genetic testing services (GSTZ1 haplotyping, HIV/HCV subpopulation assays) for personalized pharmaceutical dosing. The company operates from late discovery through IND/Phase I, leveraging precision medicine to pair companion diagnostics with its therapeutic pipeline.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • FDA Phase III clinical trial completed for DCA treatment of PDCD
+2 more records
Product overview1 text field

Medosome Biotec is a pediatric biotechnology company developing a portfolio of therapeutic drugs and genetic diagnostic tests. The therapeutic pipeline includes: Dichloroacetate (DCA) for Pyruvate Dehydrogenase Complex Deficiency; MyeGen-0298 for demyelinating diseases; Nuteric anti-diarrheal beverage; a Lactobacillus-based oral delivery platform for peptide/protein drugs including GLP-1; and Ang-(1-7) for diabetic retinopathy. The genetic testing portfolio includes GSTZ1 haplotyping for personalized DCA dosing and NextGen sequencing assays for HIV/HCV subpopulation detection. The company operates a CLIA-certified, CAP-accredited clinical genetic testing laboratory supporting its precision medicine focus.

Product and service8 records
1Dichloroacetate (DCA)
CategoryTherapeutic Drug
Description

Small molecule drug for the treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD) and other indications including pulmonary arterial hypertension, diabetes, heart disease, cancer, and sepsis.

2MyeGen-0298
CategoryTherapeutic Drug
Description

Small molecule drug that stimulates myelinating cells (oligodendrocytes) and myelin formation for the treatment of demyelinating diseases including periventricular leukomalacia (PL) and multiple sclerosis (MS).

3Nuteric
CategoryTherapeutic Beverage
Description

Anti-diarrheal beverage with pro-absorptive and anti-secretory properties for the treatment of pediatric diarrhea.

4Lactobacillus Based Platform (LBP)
CategoryDrug Delivery Platform
Description

Probiotics-based oral delivery system for peptide and protein drugs including GLP-1, using Lactobacillus bacteria for robust, scalable, and cost-effective oral delivery of therapeutics.

5Ang-(1-7) Biological Drug
CategoryTherapeutic Drug
Description

Biological drug for the treatment of diabetic retinopathy and other vascular disorders, delivered orally via probiotic-produced Angiotensin-(1-7) using Lactobacillus bacteria.

6GSTZ1 Haplotyping Test
CategoryGenetic Test
Description

Genetic test for determining GSTZ1 haplotype variations that influence dichloroacetate (DCA) metabolism kinetics, distinguishing 'fast' and 'slow' drug metabolizers for personalized DCA dosing.

7NextGen Sequencing Assay for HIV/HCV
CategoryGenetic Test
Description

Highly sensitive next-generation sequencing assay for detecting HIV and HCV subpopulations, including minor drug-resistant variants not detectable in standard commercial assays, for personalized antiretroviral drug dosing.

8Companion Diagnostics and Laboratory Developed Tests
CategoryDiagnostic Services
Description

Genetic tests for rare disease diagnosis and personalized pharmaceutical drug dosing, forming the company's precision medicine initiative.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic partner that submitted New Drug Application (NDA) for marketing approval to the FDA in August 2024 for dichloroacetate (DCA) treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD). This partnership represents a key milestone in bringing their drug to market.

2ICDDR,B (International Centre for Diarrhoeal Disease Research, Bangladesh)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

International research institution collaborating on clinical trial for Nuteric pediatric diarrhea treatment in Bangladesh. The collaboration focuses on evaluating safety and efficacy of the anti-diarrheal beverage.

mdbiotec.com
3Academic Researchers and University Technology Transfer Offices
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with faculty members to prepare and submit SBIR/STTR grant proposals. Upon funding, Medosome works collaboratively toward submitting IND applications to FDA. Faculty collaborators benefit from spin-off company formations.

mdbiotec.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Strategic alignment with clinical-stage pharmaceutical companies to advance promising drugs toward FDA marketing approval and commercialization. Medosome focuses on early-stage technologies while partners provide clinical development capabilities.

5Nuteric Natural Health Products, LLC
Strategic tierMinorTypeOEM/ Whitelabel/ Licensing Partner
Description

Spin-off subsidiary company formed to commercialize the line of products promoting GI health, including the Nuteric anti-diarrheal beverage.

mdbiotec.com
6Gifting Health
Strategic tierMinorTypeOthers
Description

Non-profit organization formed to promote GI health in developing countries, complementing the commercial efforts of Nuteric Natural Health Products.

mdbiotec.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage rare disease pharmaceutical company and Medosome's strategic partner for DCA commercialization. Directly comparable as a small rare-disease-focused drug developer handling FDA approval and launch for niche indications.

TypeDirect peer
Description

Commercial-stage rare and ultra-rare disease biotech with multiple late-stage programs and approved products. Comparable in targeting genetically defined rare diseases with limited treatment options, though at meaningfully greater scale.

TypeBroad incumbent
Description

Established rare disease biotech with a portfolio of approved therapies, particularly in pediatric metabolic and genetic conditions. Comparable as a rare-disease commercial-stage operator, though substantially larger and more diversified.

TypeDirect peer
Description

Small-cap rare disease biotech focused on pediatric disorders. Comparable in size and stage to Medosome, with a single lead rare-disease program advancing through late-stage development toward FDA approval.

TypeBroad incumbent
Description

Major rare disease franchise within AstraZeneca with commercialized orphan therapies and companion diagnostics. Relevant comparator for Medosome's rare-disease + diagnostic positioning, though operating at pharma scale.

TypeBroad incumbent
Description

Established clinical genetic testing and companion diagnostics company. Comparable to Medosome's CLIA-certified genetic testing laboratory operations and companion diagnostic strategy, though broader in scope and public-market scale.

TypeBroad incumbent
Description

Clinical genetic testing and molecular diagnostics company with CLIA-certified laboratory operations. Comparable as a CLIA-certified lab offering precision-medicine tests, particularly relevant to Medosome's companion diagnostic business.

TypeEmerging player
Description

Clinical-stage company developing defined bacterial consortia and live biotherapeutic products. Comparable to Medosome's Lactobacillus-based oral peptide/protein delivery platform approach to microbial therapeutics.

TypeDirect peer
Description

Small-cap biotech focused on autoimmune and rare disease therapeutics with FDA-approved product. Comparable as a similarly sized rare-disease-focused company that advanced a niche therapy through FDA approval.

TypeBroad incumbent
Description

Established rare disease business unit of Recordati, commercializing treatments for orphan and rare conditions globally. Relevant comparator for the eventual commercialization phase of Medosome's rare disease assets, particularly in the metabolic disorder space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature7 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medosome Biotec

Pediatric Biopharmaceuticalsmdbiotec.com

Medosome Biotec firmographics

Firmographics
Name
Medosome Biotec
Legal name
Medosome Biotec, LLC
Website
https://mdbiotec.com
Company type
Private
Operating status
Operating
Ownership category
akta.pro rank

Medosome Biotec industry classification

Industry
Product category
Pediatric Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Medical Laboratories (621511), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAIAA
Genetic & Genomic Rare Disease Therapeutics
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Pediatric biotechnology
  • Rare disease therapeutics
  • Precision medicine diagnostics
  • Probiotic drug delivery
  • Companion diagnostics

Where Medosome Biotec is headquartered

Location

Headquarters

HQ city
Alachua
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Medosome Biotec business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Drug Development and Commercialization: Developing early-stage technologies from preclinical through IND/Phase I, with strategic partnerships for FDA marketing approval and commercialization of pharmaceutical products.
  2. Genetic Testing Services: CLIA certified genetic testing laboratory providing companion diagnostics including GSTZ1 haplotyping and HIV/HCV subpopulation testing for personalized dosing.
  3. SBIR/STTR Grant Funding: Pursuing Small Business Innovation Research and Small Business Technology Transfer grants from government agencies including HHS/NIH, NSF, DOD, DOE, USDA.
  4. Spin-off Companies: Formation of subsidiary companies like Nuteric Natural Health Products for commercializing product lines, with faculty collaborators benefiting from spin-off entities.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPrecision medicine and genetic testing services

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Medosome Biotec product offering

Product offering

Core offering

Medosome Biotec develops and commercializes early-stage biotechnologies for pediatric rare and tropical diseases, including small molecule drugs (DCA, MyeGen-0298), a Lactobacillus-based oral peptide delivery platform, biological therapeutics (Ang-(1-7)), and CLIA-certified genetic testing services (GSTZ1 haplotyping, HIV/HCV subpopulation assays) for personalized pharmaceutical dosing. The company operates from late discovery through IND/Phase I, leveraging precision medicine to pair companion diagnostics with its therapeutic pipeline.

Product overview

Medosome Biotec is a pediatric biotechnology company developing a portfolio of therapeutic drugs and genetic diagnostic tests. The therapeutic pipeline includes: Dichloroacetate (DCA) for Pyruvate Dehydrogenase Complex Deficiency; MyeGen-0298 for demyelinating diseases; Nuteric anti-diarrheal beverage; a Lactobacillus-based oral delivery platform for peptide/protein drugs including GLP-1; and Ang-(1-7) for diabetic retinopathy. The genetic testing portfolio includes GSTZ1 haplotyping for personalized DCA dosing and NextGen sequencing assays for HIV/HCV subpopulation detection. The company operates a CLIA-certified, CAP-accredited clinical genetic testing laboratory supporting its precision medicine focus.

Differentiator

Problem solved

Functional benefit

Brands

  • Nuteric: Anti-diarrheal beverage for pediatric diarrhea with pro-absorptive and anti-secretory properties, currently in clinical trial in Bangladesh
  • MyeGen-0298
  • LBP (Lactobacillus Based Platform)
  • GSTZ1 Haplotyping Test
  • HIV/HCV Subpopulation Assay

Products and services

  • Dichloroacetate (DCA) Small molecule drug for the treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD) and other indications including pulmonary arterial hypertension, diabetes, heart disease, cancer, and sepsis.
  • MyeGen-0298 Small molecule drug that stimulates myelinating cells (oligodendrocytes) and myelin formation for the treatment of demyelinating diseases including periventricular leukomalacia (PL) and multiple sclerosis (MS).
  • Nuteric Anti-diarrheal beverage with pro-absorptive and anti-secretory properties for the treatment of pediatric diarrhea.
  • Lactobacillus Based Platform (LBP) Probiotics-based oral delivery system for peptide and protein drugs including GLP-1, using Lactobacillus bacteria for robust, scalable, and cost-effective oral delivery of therapeutics.
  • Ang-(1-7) Biological Drug Biological drug for the treatment of diabetic retinopathy and other vascular disorders, delivered orally via probiotic-produced Angiotensin-(1-7) using Lactobacillus bacteria.
  • GSTZ1 Haplotyping Test Genetic test for determining GSTZ1 haplotype variations that influence dichloroacetate (DCA) metabolism kinetics, distinguishing 'fast' and 'slow' drug metabolizers for personalized DCA dosing.
  • NextGen Sequencing Assay for HIV/HCV Highly sensitive next-generation sequencing assay for detecting HIV and HCV subpopulations, including minor drug-resistant variants not detectable in standard commercial assays, for personalized antiretroviral drug dosing.
  • Companion Diagnostics and Laboratory Developed Tests Genetic tests for rare disease diagnosis and personalized pharmaceutical drug dosing, forming the company's precision medicine initiative.

Quantifiable outcome

  • FDA Phase III clinical trial completed for DCA treatment of PDCD
  • +2 more outcomes

Companies that use Medosome Biotec

Customer profile

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Medosome Biotec technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature7 records

Medosome Biotec partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Saol TherapeuticscoreStrategic or Co-development PartnerStrategic partner that submitted New Drug Application (NDA) for marketing approval to the FDA in August 2024 for dichloroacetate (DCA) treatment of Pyruvate Dehydrogenase Complex Deficiency (PDCD). This partnership represents a key milestone in bringing their drug to market.
  • ICDDR,B (International Centre for Diarrhoeal Disease Research, Bangladesh)coreStrategic or Co-development PartnerInternational research institution collaborating on clinical trial for Nuteric pediatric diarrhea treatment in Bangladesh. The collaboration focuses on evaluating safety and efficacy of the anti-diarrheal beverage.
  • Academic Researchers and University Technology Transfer OfficescoreStrategic or Co-development PartnerPartnership with faculty members to prepare and submit SBIR/STTR grant proposals. Upon funding, Medosome works collaboratively toward submitting IND applications to FDA. Faculty collaborators benefit from spin-off company formations.
  • Clinical-Stage Pharmaceutical CompaniescoreStrategic or Co-development PartnerStrategic alignment with clinical-stage pharmaceutical companies to advance promising drugs toward FDA marketing approval and commercialization. Medosome focuses on early-stage technologies while partners provide clinical development capabilities.
  • Nuteric Natural Health Products, LLCminorOEM/ Whitelabel/ Licensing PartnerSpin-off subsidiary company formed to commercialize the line of products promoting GI health, including the Nuteric anti-diarrheal beverage.
  • Gifting HealthminorOthersNon-profit organization formed to promote GI health in developing countries, complementing the commercial efforts of Nuteric Natural Health Products.

Scale indicators6 records

Recent moves8 records

Expansion highlights3 records

Medosome Biotec competitors and assessment

Company assessment

Direct peers

  • Saol Therapeutics: Clinical-stage rare disease pharmaceutical company and Medosome's strategic partner for DCA commercialization. Directly comparable as a small rare-disease-focused drug developer handling FDA approval and launch for niche indications.
  • Ultragenyx Pharmaceutical: Commercial-stage rare and ultra-rare disease biotech with multiple late-stage programs and approved products. Comparable in targeting genetically defined rare diseases with limited treatment options, though at meaningfully greater scale.
  • Soleno Therapeutics: Small-cap rare disease biotech focused on pediatric disorders. Comparable in size and stage to Medosome, with a single lead rare-disease program advancing through late-stage development toward FDA approval.
  • Provention Bio: Small-cap biotech focused on autoimmune and rare disease therapeutics with FDA-approved product. Comparable as a similarly sized rare-disease-focused company that advanced a niche therapy through FDA approval.

Broad incumbents

  • BioMarin Pharmaceutical: Established rare disease biotech with a portfolio of approved therapies, particularly in pediatric metabolic and genetic conditions. Comparable as a rare-disease commercial-stage operator, though substantially larger and more diversified.
  • Alexion (AstraZeneca Rare Disease): Major rare disease franchise within AstraZeneca with commercialized orphan therapies and companion diagnostics. Relevant comparator for Medosome's rare-disease + diagnostic positioning, though operating at pharma scale.
  • Myriad Genetics: Established clinical genetic testing and companion diagnostics company. Comparable to Medosome's CLIA-certified genetic testing laboratory operations and companion diagnostic strategy, though broader in scope and public-market scale.
  • Natera: Clinical genetic testing and molecular diagnostics company with CLIA-certified laboratory operations. Comparable as a CLIA-certified lab offering precision-medicine tests, particularly relevant to Medosome's companion diagnostic business.
  • Recordati Rare Diseases: Established rare disease business unit of Recordati, commercializing treatments for orphan and rare conditions globally. Relevant comparator for the eventual commercialization phase of Medosome's rare disease assets, particularly in the metabolic disorder space.

Emerging players

  • Vedanta Biosciences: Clinical-stage company developing defined bacterial consortia and live biotherapeutic products. Comparable to Medosome's Lactobacillus-based oral peptide/protein delivery platform approach to microbial therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Medosome Biotec compliance and trust

Trust signal

Compliance2 records

Medosome Biotec financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medosome Biotec leadership team

Management profile

Number of profiles

Profiles1 record

Medosome Biotec subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Medosome Biotec funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medosome Biotec M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medosome Biotec

What does Medosome Biotec do?

Medosome Biotec develops and commercializes early-stage biotechnologies for pediatric rare and tropical diseases, including small molecule drugs (DCA, MyeGen-0298), a Lactobacillus-based oral peptide delivery platform, biological therapeutics (Ang-(1-7)), and CLIA-certified genetic testing services (GSTZ1 haplotyping, HIV/HCV subpopulation assays) for personalized pharmaceutical dosing. The company operates from late discovery through IND/Phase I, leveraging precision medicine to pair companion diagnostics with its therapeutic pipeline.

Is Medosome Biotec a public or private company?

Medosome Biotec is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Medosome Biotec founded?

Medosome Biotec was founded in -1.

Where is Medosome Biotec based?

Medosome Biotec is headquartered in Alachua, United States, in the North America region.

How does Medosome Biotec make money?

Four revenue lines are on record. Drug Development and Commercialization is the primary driver. The others are genetic Testing Services, SBIR/STTR Grant Funding and spin-off Companies.

Who are Medosome Biotec's main competitors?

Direct peers on record are Saol Therapeutics, Ultragenyx Pharmaceutical, Soleno Therapeutics and Provention Bio. Broad incumbents are BioMarin Pharmaceutical, Alexion (AstraZeneca Rare Disease), Myriad Genetics, Natera and Recordati Rare Diseases. Vedanta Biosciences is listed as an emerging player.

Does Medosome Biotec have an API?

No public API is recorded for Medosome Biotec.

What industry is Medosome Biotec in?

Medosome Biotec's product category is Pediatric Biopharmaceuticals. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAIAIAA, Genetic & Genomic Rare Disease Therapeutics. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals